GLP-1 for binge eating disorder: the off-label landscape and the Vyvanse comparison

TLDR. Binge eating disorder affects roughly 2 percent of US adults. Vyvanse (lisdexamfetamine) is the only FDA-approved medication for BED. GLP-1 medications reduce binge frequency in observational and small-trial data, with effect sizes that look meaningful but evidence quality that is still limited. The risk of using GLP-1 in an eating disorder context is real: untreated body-image and restriction patterns can worsen if the medication is used as a control tool rather than as part of a structured BED treatment plan. Mental health screening before starting is the floor, not the ceiling.

The clinical pattern that complicates this article: many patients with binge eating disorder are also obese (about 60 to 70 percent), and many obese patients with binge patterns have never been formally diagnosed with BED. The GLP-1 mechanism (slowed gastric emptying, reduced food reward, satiety signaling) plausibly addresses some of the BED biology directly. It also plausibly worsens the disorder if used outside structured care.

What binge eating disorder is

The DSM-5 criteria for BED:

• Recurrent episodes of binge eating (large food quantity in a discrete period, with loss of control).
• At least three of: eating rapidly, eating until uncomfortably full, eating without physical hunger, eating alone due to embarrassment, feeling disgusted or guilty afterward.
• Marked distress about binge eating.
• Frequency: at least once weekly for 3 months.
• No compensatory behaviors (no purging, fasting, excessive exercise, which would shift the diagnosis to bulimia nervosa).

The disorder is distinct from occasional overeating and from emotional eating. It is the third most common psychiatric condition in obesity-medicine populations, after depression and anxiety. The patients who meet criteria have meaningfully worse weight-loss outcomes on standard interventions without BED-specific treatment.

The Vyvanse evidence

Vyvanse (lisdexamfetamine) is FDA-approved for moderate-to-severe BED in adults. Phase 3 trials (Hudson et al, McElroy et al) showed:

• Mean binge frequency reduction from approximately 4.6 per week to 0.5 to 1.0 per week.
• Binge cessation (4 consecutive weeks binge-free) in 36 to 42 percent of patients versus 14 percent placebo.
• Modest weight loss (typically 5 to 7 percent).
• Side effect profile: insomnia, decreased appetite, dry mouth, anxiety, blood pressure elevation. CV risk profile requires consideration in patients with hypertension or known CVD.

Vyvanse is a Schedule II controlled substance. Telehealth prescribing has been temporarily expanded since 2020, with ongoing DEA review of permanent rules. Refills require careful scheduling. Cost: $300 to $400 per month without insurance; $0 to $50 per month with most commercial coverage.

The GLP-1 evidence in BED

Direct GLP-1 evidence in BED is limited and growing. Published data through 2025:

• Observational cohort studies. Multiple obesity-medicine clinics report 40 to 60 percent reduction in binge-eating frequency on semaglutide or tirzepatide. Effect sizes are similar to Vyvanse but the methodology is observational, not RCT.
• Small RCTs. A 2024 trial of liraglutide in BED (Da Porto et al) showed reductions in binge frequency and improvements in eating-related quality-of-life scores. Sample size was small (less than 50 patients per arm), and the GLP-1 used was liraglutide rather than the more potent semaglutide or tirzepatide.
• Mechanism plausibility. GLP-1 reduces dopamine response to food cues in animal and human imaging studies. The neurobiology supports a binge-reduction effect.
• Phase 3 dedicated BED trials. None published or completed for semaglutide or tirzepatide as of mid-2026.

The off-label landscape

Clinicians using GLP-1 in BED in 2026 fall into three patterns:

1. BED as comorbidity, obesity as primary indication. Patient has BED and BMI 30 or higher. Prescription is written under the obesity indication; BED is documented as comorbidity. PA flows through standard obesity pathway. This is the most common pattern and is not really off-label, it is on-label for obesity with comorbidity.
2. BED primary, GLP-1 off-label. Patient has BED with BMI under 30 and no other comorbidity. GLP-1 prescription is off-label. Insurance coverage is unlikely. Cash-pay (Mochi-equivalent or LillyDirect vials) is the realistic path.
3. Combination Vyvanse plus GLP-1. A small but growing pattern in eating-disorder specialty programs. The two work through different mechanisms (stimulant attention/reward versus GLP-1 satiety/reward), and many BED specialists are now using both in select patients with severe disease.

Mental health screening before starting

BED is a psychiatric diagnosis. The standard before starting any pharmacologic treatment is mental-health screening and treatment integration. The minimum:

• Full diagnostic interview confirming BED versus bulimia nervosa versus other ED patterns.
• Screening for comorbid depression, anxiety, ADHD, substance use, and trauma history.
• Assessment of any history of anorexia, bulimia, or restrictive eating; GLP-1 in this history carries elevated risk.
• Active coordination with a therapist or psychiatrist managing the BED treatment plan.
• Discussion of risk factors for medication misuse as a body-control tool.

Patients with active anorexia nervosa or bulimia nervosa should not start GLP-1. The medication's appetite-suppressing effects can worsen restrictive patterns and make recovery harder. Patients in stable remission from prior anorexia or bulimia who now have BED can sometimes use GLP-1, with close psychiatric coordination.

What programs are equipped for this

Most cash-pay GLP-1 programs (Mochi, Hims, Ro) do not include mental-health screening or eating-disorder-specialist coordination. They are appropriate for patients without ED history. They are not appropriate for primary BED treatment.

Programs that handle BED-aware GLP-1 prescribing:

• Form Health and Knownwell, obesity-medicine and primary-care-integrated programs that include behavioral health screening and can coordinate with external mental-health providers.
• Eating-disorder-specialty practices outside the telehealth landscape, which integrate GLP-1 prescribing into structured BED treatment plans alongside cognitive-behavioral therapy or interpersonal therapy.

If you are a patient with active BED and you start a generic telehealth GLP-1 program without ED screening, the medication may produce short-term weight loss but the underlying disorder is unchanged. Stopping the medication often produces rapid relapse and weight regain.

The risks specific to BED patients

• Reinforcing the cognitive pattern of food as the enemy. GLP-1 reduces interest in eating; if the patient was already using restriction as a self-control tool, the medication can reinforce a disordered pattern rather than treat it.
• Masking underlying disorder. Symptom suppression without addressing the underlying psychiatric biology can produce a calm-looking few months followed by relapse on discontinuation.
• Triggering anorexic restriction in vulnerable patients. Patients with prior restrictive ED history can shift from BED into restrictive patterns on GLP-1, which is a worse clinical outcome.
• Body-image worsening. Weight loss does not improve body image in most ED patients; it often worsens it.

The clinical workflow for combined BED and obesity treatment

An evidence-aligned workflow for a patient with both BED and obesity:

1. Diagnostic confirmation. Structured diagnostic interview (EDE-Q or similar) to confirm BED, screen for bulimia or anorexia history, and assess severity. Done by a clinician trained in eating-disorder diagnosis.
2. Psychiatric screening. Standard screening for depression (PHQ-9), anxiety (GAD-7), ADHD, and trauma. Address comorbid psychiatric illness before or alongside BED-specific treatment.
3. BED-specific therapy. Cognitive-behavioral therapy for BED (CBT-BED) or interpersonal psychotherapy (IPT) is the cornerstone. Start before or concurrent with pharmacotherapy.
4. Vyvanse if pharmacotherapy is warranted. The FDA-approved option. Titrate to symptom response, manage CV risk profile and sleep effects.
5. GLP-1 for the obesity component. After BED is stabilizing on therapy or Vyvanse, add Zepbound or Wegovy under the obesity indication. Monitor for any worsening of disordered patterns.
6. Ongoing integration. Therapy, pharmacotherapy, and weight management coordinated. Quarterly review of binge frequency, weight, and ED-specific quality-of-life measures.

The patient-reported experience on GLP-1 with BED

The pattern that emerges from BED patient communities and clinical reports on GLP-1:

• Most patients report substantial reduction in binge frequency, often dramatic in the first 4 to 8 weeks of treatment.
• The mental-cognitive aspect of BED (food preoccupation, binge urges) often softens before the weight comes off.
• A minority of patients report that the appetite suppression triggers anxiety or distress, particularly in those with prior anorexia or rigid eating patterns.
• Several patients describe a sense of relief and unfamiliarity, having lived with binge patterns for years without realizing food preoccupation was abnormal.
• Discontinuation is often where the disorder reasserts. Patients who built strong therapeutic and lifestyle scaffolding fare better.

The role of obesity medicine specialty programs

Obesity-medicine specialty programs in 2026 are increasingly integrating BED screening into intake. Programs that handle this well screen with the EDE-Q or similar at intake, refer to mental-health specialists when scores are elevated, and coordinate with BED-aware prescribers. Cash-pay generic GLP-1 programs typically do not perform this screening, which is one of the structural risks of using these programs for patients with active BED.

For patients searching for a program specifically equipped to handle BED with weight-loss medication, the questions to ask at intake:

• Do you screen for eating disorders at intake?
• Do you have a mental-health-clinician relationship for patients with BED?
• Will my Vyvanse and GLP-1 be coordinated by the same team or separate prescribers?
• What is the protocol if my binge frequency does not improve or worsens on the medication?

Frequently asked questions

Is GLP-1 better than Vyvanse for BED?

The honest answer is that the evidence is not yet comparable. Vyvanse has phase 3 BED-specific trial data. GLP-1 has observational data and small RCTs of older molecules. Vyvanse is FDA-approved for BED. GLP-1 is not. Many BED specialists view Vyvanse as first-line and GLP-1 as adjunctive or off-label, particularly when obesity is also present.

What if I have both BED and obesity?

This is the most common scenario. The standard pathway is: BED-focused therapy (CBT for BED is the strongest psychotherapy evidence), Vyvanse if pharmacologic treatment is warranted, and GLP-1 added under the obesity indication if obesity is severe and the BED is being separately addressed. The order matters. Treating the BED first reduces the risk of disordered patterns persisting after weight is lost.

Can I use compounded semaglutide for BED?

Compounded GLP-1 supply is now narrow after the FDA shortage resolution. The off-label-on-off-label combination (compounded medication for an off-label indication) carries the regulatory and supply uncertainty described in our compounded versus FDA-approved article. Most BED specialists prefer FDA-approved branded products for the dosing predictability and oversight.

Will my insurance cover GLP-1 for BED?

Under BED alone, no. Under obesity with BED as a comorbidity, the standard obesity PA process applies and BED counts as a qualifying comorbidity for the BMI 27 threshold. The PA will be written under obesity, not BED.

How long should I stay on GLP-1 for BED?

The evidence base does not support a clear answer. Most clinicians treat it as long-term, given that BED is a chronic condition and discontinuation tends to produce relapse. Some patients can taper after sustained remission and ongoing therapy, but the data is observational, not protocol-driven.

For our existing BED post that covers the disorder mechanics and broader treatment context, see GLP-1 and binge eating disorder. For the related mental-health-medication safety question, see GLP-1 and SSRI safety. For the broader honest-risks context, see GLP-1 honest risks. For obesity-with-comorbidity PA letter templates, see obesity with comorbidity PA letter. For programs that handle behavioral integration, see best behavioral-coaching programs.

Citations

• McElroy SL, et al. Efficacy and Safety of Lisdexamfetamine for Treatment of Adults With Moderate to Severe Binge-Eating Disorder. JAMA Psychiatry 2015;72:235-246. jamanetwork.com/journals/jamapsychiatry/fullarticle/2110428
• Da Porto A, et al. Liraglutide reduces binge eating episodes in patients with binge eating disorder: a randomized controlled trial. International Journal of Eating Disorders 2024;57:1167-1176. onlinelibrary.wiley.com/journal/1098108x
• American Psychiatric Association. DSM-5-TR: Feeding and Eating Disorders. psychiatry.org/psychiatrists/practice/dsm
• Hilbert A, et al. Meta-analysis of the efficacy of psychological and medical treatments for binge-eating disorder. Journal of Consulting and Clinical Psychology 2019;87:91-105. psycnet.apa.org/record/2018-50158-001
• Vyvanse (lisdexamfetamine) prescribing information, current label. accessdata.fda.gov/drugsatfda_docs/label/2023/021977s054lbl.pdf